Last reviewed · How we verify

Lenvatinib, tislelizumab, gemcitabine and cisplatin

Second Affiliated Hospital, School of Medicine, Zhejiang University · Phase 3 active Small molecule

Lenvatinib, tislelizumab, gemcitabine and cisplatin is a Multi-targeted tyrosine kinase inhibitor + PD-1 inhibitor + chemotherapy combination Small molecule drug developed by Second Affiliated Hospital, School of Medicine, Zhejiang University. It is currently in Phase 3 development for Advanced or metastatic solid tumors (Phase 3 trial indication under investigation).

This combination uses lenvatinib to inhibit multiple receptor tyrosine kinases, tislelizumab to block PD-1 immune checkpoints, and gemcitabine/cisplatin as cytotoxic chemotherapy agents to attack cancer cells through multiple pathways.

This combination uses lenvatinib to inhibit multiple receptor tyrosine kinases, tislelizumab to block PD-1 immune checkpoints, and gemcitabine/cisplatin as cytotoxic chemotherapy agents to attack cancer cells through multiple pathways. Used for Advanced or metastatic solid tumors (Phase 3 trial indication under investigation).

At a glance

Generic nameLenvatinib, tislelizumab, gemcitabine and cisplatin
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University
Drug classMulti-targeted tyrosine kinase inhibitor + PD-1 inhibitor + chemotherapy combination
TargetFGFR, VEGFR, RET (lenvatinib); PD-1 (tislelizumab); DNA (gemcitabine, cisplatin)
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Lenvatinib is a multi-targeted tyrosine kinase inhibitor that blocks FGFR, VEGFR, RET, and other kinases to inhibit angiogenesis and tumor growth. Tislelizumab is a humanized PD-1 inhibitor that restores anti-tumor immune responses by blocking the PD-1/PD-L1 axis. Gemcitabine and cisplatin are conventional chemotherapy agents that cause DNA damage and cell death. Together, this quadruple combination targets tumor vasculature, immune evasion, and direct cytotoxicity.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Lenvatinib, tislelizumab, gemcitabine and cisplatin

What is Lenvatinib, tislelizumab, gemcitabine and cisplatin?

Lenvatinib, tislelizumab, gemcitabine and cisplatin is a Multi-targeted tyrosine kinase inhibitor + PD-1 inhibitor + chemotherapy combination drug developed by Second Affiliated Hospital, School of Medicine, Zhejiang University, indicated for Advanced or metastatic solid tumors (Phase 3 trial indication under investigation).

How does Lenvatinib, tislelizumab, gemcitabine and cisplatin work?

This combination uses lenvatinib to inhibit multiple receptor tyrosine kinases, tislelizumab to block PD-1 immune checkpoints, and gemcitabine/cisplatin as cytotoxic chemotherapy agents to attack cancer cells through multiple pathways.

What is Lenvatinib, tislelizumab, gemcitabine and cisplatin used for?

Lenvatinib, tislelizumab, gemcitabine and cisplatin is indicated for Advanced or metastatic solid tumors (Phase 3 trial indication under investigation).

Who makes Lenvatinib, tislelizumab, gemcitabine and cisplatin?

Lenvatinib, tislelizumab, gemcitabine and cisplatin is developed by Second Affiliated Hospital, School of Medicine, Zhejiang University (see full Second Affiliated Hospital, School of Medicine, Zhejiang University pipeline at /company/second-affiliated-hospital-school-of-medicine-zhejiang-university).

What drug class is Lenvatinib, tislelizumab, gemcitabine and cisplatin in?

Lenvatinib, tislelizumab, gemcitabine and cisplatin belongs to the Multi-targeted tyrosine kinase inhibitor + PD-1 inhibitor + chemotherapy combination class. See all Multi-targeted tyrosine kinase inhibitor + PD-1 inhibitor + chemotherapy combination drugs at /class/multi-targeted-tyrosine-kinase-inhibitor-pd-1-inhibitor-chemotherapy-combination.

What development phase is Lenvatinib, tislelizumab, gemcitabine and cisplatin in?

Lenvatinib, tislelizumab, gemcitabine and cisplatin is in Phase 3.

What are the side effects of Lenvatinib, tislelizumab, gemcitabine and cisplatin?

Common side effects of Lenvatinib, tislelizumab, gemcitabine and cisplatin include Hypertension, Diarrhea, Fatigue, Nausea/vomiting, Myelosuppression, Immune-related adverse events.

What does Lenvatinib, tislelizumab, gemcitabine and cisplatin target?

Lenvatinib, tislelizumab, gemcitabine and cisplatin targets FGFR, VEGFR, RET (lenvatinib); PD-1 (tislelizumab); DNA (gemcitabine, cisplatin) and is a Multi-targeted tyrosine kinase inhibitor + PD-1 inhibitor + chemotherapy combination.

Related